<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03505840</url>
  </required_header>
  <id_info>
    <org_study_id>vocal in placenta</org_study_id>
    <nct_id>NCT03505840</nct_id>
  </id_info>
  <brief_title>The Value of Placental Vascularization and Placental Volume in Pregnancy</brief_title>
  <official_title>TheValue of Placental Vascularization Indices and Placental Volume in Pregnancies With Antiphospholipid Syndrome for Prediction of Neonatal Outcome&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aljazeera Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Aljazeera Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antiphospholipid antibodies are autoantibodies directed against phospholipid‐binding
      proteins. Among these groups of antibodies, lupus anticoagulant (LA) and anticardiolipin
      antibodies (aCL)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      APLS can be primary when no evidence of autoimmune disease is found, or secondary to
      autoimmune processes like systemic lupus erythematous (SLE) in a 40% of the cases.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 21, 2018</start_date>
  <completion_date type="Anticipated">January 10, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The number of participants who will have impaired placental doppler indices</measure>
    <time_frame>within 2 months</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Antiphospholipid Syndrome in Pregnancy</condition>
  <arm_group>
    <arm_group_label>antiphospholipid group</arm_group_label>
    <description>pregnant ladies in the third trimester who have antiphospholipid syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>pregnant ladies in the third trimester who have no medical disorders with pregnancy</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Ultrasound with Doppler and 3D technology</intervention_name>
    <description>ultrasound will be made to pregnant females in 3rd trimester with doppler and 3D technology</description>
    <arm_group_label>antiphospholipid group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Singleton pregnancy.

          -  Gestational age of 34‐37 weeks.

          -  Pregnant women with antiphospholipid syndrome
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Singleton pregnancy.

               -  Gestational age of 34‐37 weeks.

               -  Pregnant women with antiphospholipid syndrome

        Exclusion Criteria:

          -  Twin or multiple pregnancies.

          -  Congenital fetal anomalies.

          -  Gestational age of less than 34.

          -  Gestational age of more than 37.

          -  Women with placental or umbilical artery anomalies.

          -  Antepartum hemorrhage (placental abruption, placenta previa and vasa previa).

          -  Posterior placenta.

          -  History of rupture of membrane.

          -  Patient refusal or fall outs.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>pregnant females with antiphospholipid syndrome</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahmoud Alalfy</last_name>
    <role>Principal Investigator</role>
    <affiliation>Algazeerah hospital -Location (Giza -Egypt ) and National Research centre egypt</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mahmoud Alalfy</last_name>
    <phone>01002611058</phone>
    <email>mahmoudalalfy@ymail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Algazeerah</name>
      <address>
        <city>Giza</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mahmoud Alalfy, master</last_name>
      <phone>+201002611058</phone>
      <email>mahmoudalalfy@ymail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ahmed Elgazzar, M.D</last_name>
      <phone>+201014005959</phone>
    </contact_backup>
    <investigator>
      <last_name>Mahmoud Alalfy, master</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 13, 2018</study_first_submitted>
  <study_first_submitted_qc>April 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 23, 2018</study_first_posted>
  <last_update_submitted>April 20, 2018</last_update_submitted>
  <last_update_submitted_qc>April 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aljazeera Hospital</investigator_affiliation>
    <investigator_full_name>Mahmoud Alalfy</investigator_full_name>
    <investigator_title>Assistant Researcher , National Research centre and Specialist of Obstetrics and Gynecology in Aljazeerah hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Antiphospholipid Syndrome</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The research data will be published</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

